Quote this publication Share Print

EYLEA (aflibercept), anti-VEGF

OPHTHALMOLOGY - New indication
Opinions on drugs - Posted on Jan 26 2017

Reason for request

Extension of indication

Moderate clinical added value, as is the case with LUCENTIS, in visual impairment due to myopic choroidal neovascularisation

  • EYLEA has Marketing Authorisation in adults, in the treatment of visual impairment due to myopic choroidal neovascularisation (CNV).
  • A study has demonstrated a substantial improvement in visual acuity by comparison with sham intravitreal injections (+14.1 letters on the ETDRS scale).
  • Despite the absence of comparative data versus ranibizumab, EYLEA may be considered a 1st line treatment just as LUCENTIS in this indication.

Clinical Benefit

Substantial

-


Clinical Added Value

moderate

-


Therapeutic use

-

Contact Us

Évaluation des médicaments
All our publications